Answers are grounded in this paper and cite their sources.
Background and study aim: Liver biopsy couldnt be utilizedfor screening of nonalcoholic steatohepatitis (NASH), as it isconsidered invasive, and has many complications. The studyaims to investigate the value of serum levels of CK -18fragments as a diagnostic biomarker for NASH and NAFLDand its correlation with severity of NASH as measured byNAFLD activity score (NAS) of liver biopsies. Patients andmethods: A total number of 46 subjects with biopsy-provennon-alcoholic steatohepatitis (NASH group) and 54 subjectswith borderline NASH, simple steatosis and normal livertissue (non-NASH group) as well as 30 age-matched healthyvolunteers were included in the study. Scoring of liverbiopsies using the NAFLD activity score (NAS) and measurementof CK-18 in sera was done. Results: The serum level ofcytokeratin-18 was significantly higher in the NASH groupwhen compared to non-NASH group (P=0.0123) or controls(P=0.00001). Using the ROC curve, the optimal value of cytokeratin-18 was 487U/L, with sensitivity 69 % and specificity84.5 % in detecting NASH. Serum CK-18 levels were significantlycorrelated to the disease severity as measured by liverbiopsy (degree of steatosis, fibrosis, lobular inflammation,and ballooning) in NASH patients. Conclusions: Serum CK-18 could be used as a non-invasive diagnostic serum markerfor patients of NAFLD and NASH.
No takes yet. Share an insight, caveat, or question.
Habib et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: